News
3h
Zacks Investment Research on MSNWhat Analyst Projections for Key Metrics Reveal About Gilead (GILD) Q1 EarningsWall Street analysts expect Gilead Sciences (GILD) to post quarterly earnings of $1.73 per share in its upcoming report, which indicates a year-over-year increase of 231.1%. Revenues are expected to ...
2h
Zacks Investment Research on MSNHere's Why Gilead Sciences (GILD) is a Strong Value StockIt doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...
Ipsen and its fellow French partner Genfit are competing with Intercept and Advanz’s Ocaliva, which was approved in 2016 and ...
Gilead Sciences’ sponsorship of a conference Wi-Fi network has landed it in hot water. | Gilead Sciences’ sponsorship of a ...
A group of academics is arguing that countries seeking access to a groundbreaking HIV prevention drug from Gilead Sciences ...
2d
US Weekly on MSNWhat to Know About ‘The Handmaid’s Tale’ Spinoff ‘The Testaments’: Returning Cast Members and MoreHulu's spinoff of 'The Handmaid's Tale' titled 'The Testaments' comes after the original show's sixth and final season ...
Wesley Sundquist, a biochemist at University of Utah, and Tomas Cihlar, a virologist at Gilead, a biopharmaceutical company, ...
"It's not about a relationship she chose, like with Fred," Bruce Miller says, explaining why writers chose to introduce the ...
Four episodes into the final season of The Handmaid's Tale, June's (Elisabeth Moss) quest to destroy Gilead is back in full ...
As the final season of "The Handmaid's Tale" begins today, we're taking a look back on everything to know about the hit Hulu ...
Research in the Sundquist lab laid the foundations for the development of lenacapavir, a drug that prevents HIV infection ...
The resistance against Gilead carries on. Here's what you need to remember before "The Handmaid's Tale" Season 6 starts.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results